115 related articles for article (PubMed ID: 15054690)
41. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
42. [A fairer comparison between carvedilol and metoprolol is still to be done].
Johnsson G; Aberg J
Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
[No Abstract] [Full Text] [Related]
43. Which beta-blocker for heart failure?
Patel MR; Gattis W
Am Heart J; 2004 Feb; 147(2):238. PubMed ID: 14760319
[No Abstract] [Full Text] [Related]
44. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
47. Beta-adrenoceptor blockers in heart failure.
Song J; White CM
Conn Med; 1999 Dec; 63(12):719-22. PubMed ID: 10659472
[No Abstract] [Full Text] [Related]
48. Heritability of metoprolol and torsemide pharmacokinetics.
Matthaei J; Brockmöller J; Tzvetkov MV; Sehrt D; Sachse-Seeboth C; Hjelmborg JB; Möller S; Halekoh U; Hofmann U; Schwab M; Kerb R
Clin Pharmacol Ther; 2015 Dec; 98(6):611-21. PubMed ID: 26344676
[TBL] [Abstract][Full Text] [Related]
49. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA).
Fedorinov DS; Mirzaev KB; Mustafina VR; Sychev DA; Maximova NR; Chertovskikh JV; Popova NV; Tarabukina SM; Rudykh ZA
Drug Metab Pers Ther; 2018 Dec; 33(4):195-200. PubMed ID: 30325731
[TBL] [Abstract][Full Text] [Related]
50. Beta-adrenergic blockers. Choosing among them.
Vlietstra RE; McGoon MD
Postgrad Med; 1984 Sep; 76(3):71-3, 76-7, 80. PubMed ID: 6147832
[TBL] [Abstract][Full Text] [Related]
51. The development of the LC-MS/MS method based on S-9 biotransformation for detection of metabolites of selected β-adrenolytics in surface water.
Stankiewicz A; Giebułtowicz J; Stefański M; Sikorska K; Wroczyński P; Nałęcz-Jawecki G
Environ Toxicol Pharmacol; 2015 Mar; 39(2):906-16. PubMed ID: 25801322
[TBL] [Abstract][Full Text] [Related]
52. Pharmacogenomics of heart failure: a systematic review.
Mottet F; Vardeny O; de Denus S
Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
[TBL] [Abstract][Full Text] [Related]
53. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF; Estores DS; Feng K; Kim H; Kinjo M; Li Z; Fang L; Chapman AB; Cooper-DeHoff RM; Gums JG; Hamadeh IS; Zhao L; Schmidt S; Frye RF; Johnson JA; Cavallari LH
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):678-685. PubMed ID: 33067866
[TBL] [Abstract][Full Text] [Related]
54. Genetic variation, β-blockers, and perioperative myocardial infarction.
Nagele P; Liggett SB
Anesthesiology; 2011 Dec; 115(6):1316-27. PubMed ID: 21918425
[TBL] [Abstract][Full Text] [Related]
55. Interaction of cimetidine with metoprolol, propranolol, or atenolol.
Kirch W; Köhler H; Spahn H; Mutschler E
Lancet; 1981 Sep; 2(8245):531-2. PubMed ID: 6115283
[No Abstract] [Full Text] [Related]
56. Methodologic aspects of glaucoma phamacogenomic studies.
Leffler CT
Arch Ophthalmol; 2009 May; 127(5):706; author reply 706-7. PubMed ID: 19433730
[No Abstract] [Full Text] [Related]
57. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects.
Leeder JS; Gaedigk A
Pharmacogenomics; 2014 Jun; 15(8):1055-8. PubMed ID: 25084197
[No Abstract] [Full Text] [Related]
58. The pharmacokinetics of metoprolol and its metabolites in dialysis patients.
Seiler KU; Schuster KJ; Meyer GJ; Niedermayer W; Wassermann O
Clin Pharmacokinet; 1980; 5(2):192-8. PubMed ID: 7363534
[TBL] [Abstract][Full Text] [Related]
59. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenetic profiling in the treatment of heart disease.
Dorn GW
Transl Res; 2009 Dec; 154(6):295-302. PubMed ID: 19931195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
